Brief: Voyager Therapeutics Presents Robust, Multi-Species Results From Preclinical Studies Of Iv-Delivered, Tracer™-Generated Novel Capsids At The ASGCT 26Th Annual Meeting
18/05/2023 11:04
May 18 (Reuters) - Voyager Therapeutics Inc VYGR.O :
* VOYAGER THERAPEUTICS PRESENTS ROBUST, MULTI-SPECIES
RESULTS FROM
PRECLINICAL STUDIES OF IV-DELIVERED, TRACER™-GENERATED NOVEL
CAPSIDS AT THE ASGCT 26TH ANNUAL MEETING
Source text for Eikon: ID:nGNX90hd0T
Further company coverage: VYGR.O
Recent news on Voyager Therapeutics
See all newsBrief: Voyager Names Robin Swartz As President; Expected To Succeed As CEO In Q1 2027
Voyager Therapeutics, Inc. reports results for the quarter ended June 30 - Earnings Summary
Voyager Therapeutics Q2 collaboration revenue falls, net loss narrows
Brief: Voyager Therapeutics Q2 Net Income USD -24.473 Million
Voyager Therapeutics Inc expected to post a loss of 48 cents a share - Earnings Preview